The cancer-intrinsic autophagy, involving key genes like ATG3, BECN1, and RB1CC1, protects tumor cells from CD19 CAR-T cell-mediated cytotoxicity, and its inhibition sensitizes B-cell leukemia and lymphoma cells to CAR-T therapy. This evidence concerns the gene RB1CC1 and neoplasm.